Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

DXR

Daxor (DXR)

Daxor Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:DXR
DateTimeSourceHeadlineSymbolCompany
16/04/202422:00GlobeNewswire Inc.New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of CongestionNASDAQ:DXRDaxor Corporation
15/04/202422:00GlobeNewswire Inc.DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)NASDAQ:DXRDaxor Corporation
10/04/202422:00GlobeNewswire Inc.Daxor Corporation Announces New Hospital Account at Leading Chicago HospitalNASDAQ:DXRDaxor Corporation
01/04/202423:00GlobeNewswire Inc.Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24NASDAQ:DXRDaxor Corporation
25/03/202423:00GlobeNewswire Inc.Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of DiagnosticsNASDAQ:DXRDaxor Corporation
22/03/202423:00GlobeNewswire Inc.Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024NASDAQ:DXRDaxor Corporation
19/03/202405:18GlobeNewswire Inc.Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023NASDAQ:DXRDaxor Corporation
19/03/202405:18GlobeNewswire Inc.Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersNASDAQ:DXRDaxor Corporation
11/03/202423:00GlobeNewswire Inc.Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User BaseNASDAQ:DXRDaxor Corporation
09/03/202405:49Edgar (US Regulatory)Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend]NASDAQ:DXRDaxor Corporation
09/03/202400:00GlobeNewswire Inc.Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure PatientsNASDAQ:DXRDaxor Corporation
07/03/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
01/03/202409:28Edgar (US Regulatory)Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend]NASDAQ:DXRDaxor Corporation
01/03/202408:15Edgar (US Regulatory)Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report)NASDAQ:DXRDaxor Corporation
27/02/202400:00GlobeNewswire Inc.Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics ConferenceNASDAQ:DXRDaxor Corporation
13/02/202400:00GlobeNewswire Inc.Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer AcquisitionsNASDAQ:DXRDaxor Corporation
08/02/202400:00GlobeNewswire Inc.Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing AccountsNASDAQ:DXRDaxor Corporation
30/01/202400:00GlobeNewswire Inc.Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual MeetingNASDAQ:DXRDaxor Corporation
17/01/202400:00GlobeNewswire Inc.Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care CongressNASDAQ:DXRDaxor Corporation
10/01/202400:00GlobeNewswire Inc.DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMESNASDAQ:DXRDaxor Corporation
03/01/202400:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DXRDaxor Corporation
03/01/202400:30GlobeNewswire Inc.Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume AnalyzerNASDAQ:DXRDaxor Corporation
07/12/202307:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
02/12/202313:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
02/12/202313:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
02/12/202312:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
02/12/202312:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
27/11/202322:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
25/11/202305:53Edgar (US Regulatory)Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)NASDAQ:DXRDaxor Corporation
25/11/202303:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
 Showing the most relevant articles for your search:NASDAQ:DXR